Redefining High-Risk Prostate Cancer Based on Distant Metastases and Mortality After High-Dose Radiotherapy With Androgen Deprivation Therapy

Reddy, Chandana A; Stephans, Kevin L; Ciezki, Jay P; Klein, Eric A; Mahadevan, Arul; Kupelian, Patrick A

doi:10.1016/J.IJROBP.2011.04.042

Title: Redefining High-Risk Prostate Cancer Based on Distant Metastases and Mortality After High-Dose Radiotherapy With Androgen Deprivation Therapy

Full Record
Other Related Research

Abstract

Purpose: Modern outcomes of high-dose external beam radiotherapy (EBRT) with androgen deprivation therapy (ADT) for high-risk (HR) prostate cancer are not well described. Methods and Materials: We identified 585 patients who met HR criteria by 2010 National Comprehensive Cancer Network guidelines, who were treated with EBRT consisting of {>=}74 Gy from 1996 to 2008 at Cleveland Clinic, of whom 95% received ADT. We analyzed biochemical relapse-free survival (bRFS), distant metastases-free survival (DMFS), and prostate cancer-specific mortality (PCSM). Results: The median EBRT dose was 78 Gy, and median ADT duration was 6 months. At 10 years, the bRFS was 50.2%, the DMFS was 71.6%, and the PCSM was 14.4%. On multivariate analysis, significant predictors of bRFS were biopsy Gleason score (bGS) of 8 to 10, stage T3, and prostate-specific antigen (PSA) concentration; predictors of DMFS were bGS of 8 to 10 and stage T3; the only predictor of PCSM was bGS of 8 to 10. The duration of ADT was not predictive of any endpoint. We identified an unfavorable high-risk (UHR) group of stage T1-T2 tumors consisting of bGS of 8 with PSA of >10 ng/ml or bGS of 9 to 10 with any PSA level; the remaining clinically localized cancersmore »« less

Authors:

Reddy, Chandana A; Stephans, Kevin L; Ciezki, Jay P ^[1]; Klein, Eric A ^[2]; Mahadevan, Arul ^[3]; Kupelian, Patrick A ^[4]

Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio (United States)
Department of Urology, Glickman Urological Institute, Cleveland Clinic, Cleveland, Ohio (United States)
Seacoast Cancer Center New Hampshire, Dover, New Hampshire (United States)
Department of Radiation Oncology, University of California Los Angeles Health System, Los Angeles, California (United States)

Publication Date:: Thu Mar 15 00:00:00 EDT 2012

OSTI Identifier:: 22056163

Resource Type:: Journal Article

Journal Name:: International Journal of Radiation Oncology, Biology and Physics

Additional Journal Information:: Journal Volume: 82; Journal Issue: 4; Other Information: Copyright (c) 2012 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0360-3016

Country of Publication:: United States

Language:: English

Subject:: 62 RADIOLOGY AND NUCLEAR MEDICINE; ANDROGENS; ANTIGENS; BIOPSY; HAZARDS; METASTASES; MORTALITY; MULTIVARIATE ANALYSIS; NEOPLASMS; PATIENTS; PROSTATE; RADIATION DOSES; RADIOTHERAPY; RECOMMENDATIONS

Citation Formats


                    Tendulkar, Rahul D., E-mail: tendulr@ccf.org, Reddy, Chandana A, Stephans, Kevin L, Ciezki, Jay P, Klein, Eric A, Mahadevan, Arul, and Kupelian, Patrick A. Redefining High-Risk Prostate Cancer Based on Distant Metastases and Mortality After High-Dose Radiotherapy With Androgen Deprivation Therapy.  United States: N. p., 2012. 
        Web.  doi:10.1016/J.IJROBP.2011.04.042.

Copy to clipboard


                    Tendulkar, Rahul D., E-mail: tendulr@ccf.org, Reddy, Chandana A, Stephans, Kevin L, Ciezki, Jay P, Klein, Eric A, Mahadevan, Arul, & Kupelian, Patrick A. Redefining High-Risk Prostate Cancer Based on Distant Metastases and Mortality After High-Dose Radiotherapy With Androgen Deprivation Therapy.  United States.  https://doi.org/10.1016/J.IJROBP.2011.04.042

Copy to clipboard


                    Tendulkar, Rahul D., E-mail: tendulr@ccf.org, Reddy, Chandana A, Stephans, Kevin L, Ciezki, Jay P, Klein, Eric A, Mahadevan, Arul, and Kupelian, Patrick A. 2012.  
        "Redefining High-Risk Prostate Cancer Based on Distant Metastases and Mortality After High-Dose Radiotherapy With Androgen Deprivation Therapy".  United States.  https://doi.org/10.1016/J.IJROBP.2011.04.042.

Copy to clipboard


                    
@article{osti_22056163,

  title        = {Redefining High-Risk Prostate Cancer Based on Distant Metastases and Mortality After High-Dose Radiotherapy With Androgen Deprivation Therapy},

  author       = {Tendulkar, Rahul D., E-mail: tendulr@ccf.org and Reddy, Chandana A and Stephans, Kevin L and Ciezki, Jay P and Klein, Eric A and Mahadevan, Arul and Kupelian, Patrick A},

  abstractNote = {Purpose: Modern outcomes of high-dose external beam radiotherapy (EBRT) with androgen deprivation therapy (ADT) for high-risk (HR) prostate cancer are not well described. Methods and Materials: We identified 585 patients who met HR criteria by 2010 National Comprehensive Cancer Network guidelines, who were treated with EBRT consisting of {>=}74 Gy from 1996 to 2008 at Cleveland Clinic, of whom 95% received ADT. We analyzed biochemical relapse-free survival (bRFS), distant metastases-free survival (DMFS), and prostate cancer-specific mortality (PCSM). Results: The median EBRT dose was 78 Gy, and median ADT duration was 6 months. At 10 years, the bRFS was 50.2%, the DMFS was 71.6%, and the PCSM was 14.4%. On multivariate analysis, significant predictors of bRFS were biopsy Gleason score (bGS) of 8 to 10, stage T3, and prostate-specific antigen (PSA) concentration; predictors of DMFS were bGS of 8 to 10 and stage T3; the only predictor of PCSM was bGS of 8 to 10. The duration of ADT was not predictive of any endpoint. We identified an unfavorable high-risk (UHR) group of stage T1-T2 tumors consisting of bGS of 8 with PSA of >10 ng/ml or bGS of 9 to 10 with any PSA level; the remaining clinically localized cancers comprised the favorable high-risk (FHR) group. Comparing FHR, UHR, and stage T3 groups, the DMFS rates were 81.4%, 57.8%, and 59.1% (p < 0.0001), and the PCSM rates were 7.5%, 28.4%, and 20.6% at 10 years, respectively (p = 0.006). Conclusion: A bGS of 8 to 10 is the strongest predictor of bRFS, DMFS, and PCSM after high-dose EBRT with ADT. The duration of ADT did not correlate with outcome. Future studies should account for the heterogeneity in HR prostate cancer.},

  doi          = {10.1016/J.IJROBP.2011.04.042},

  url          = {https://www.osti.gov/biblio/22056163},
  journal      = {International Journal of Radiation Oncology, Biology and Physics},

  issn         = {0360-3016},

  number       = 4,

  volume       = 82,

  place        = {United States},

  year         = {Thu Mar 15 00:00:00 EDT 2012},

  month        = {Thu Mar 15 00:00:00 EDT 2012}

}

Copy to clipboard

Journal Article:

https://doi.org/10.1016/J.IJROBP.2011.04.042

Other availability

Find in Google Scholar

Search WorldCat to find libraries that may hold this journal

Save / Share:

Export Metadata

Save to My Library

Similar records in OSTI.GOV collections:

Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis–Free Survival and Prostate Cancer–Specific Mortality

Journal Article Naik, Mihir; Reddy, Chandana; Stephans, Kevin; ... - International Journal of Radiation Oncology, Biology and Physics

Objectives/Background: To determine whether a 6-month posttreatment prostate-specific antigen (PSA) value in patients with prostate cancer (PCa) treated with concurrent androgen deprivation therapy (ADT) and external beam radiation therapy (EBRT) serves as an early predictor for biochemical relapse free survival (bRFS), distant metastasis–free survival (DMFS), and prostate cancer–specific mortality (PCSM). Methods: A retrospective review of intermediate-risk and high-risk PCa patients treated with EBRT and concurrent ADT at a single institution between 1996 and 2012. All patients received high-dose radiation with either 78 Gy in 39 fractions or 70 Gy in 28 fractions. Kaplan-Meier analysis was used to estimate bRFS and DMFS, andmore »« less
https://doi.org/10.1016/J.IJROBP.2016.07.009
Continued Benefit to Androgen Deprivation Therapy for Prostate Cancer Patients Treated With Dose-Escalated Radiation Therapy Across Multiple Definitions of High-Risk Disease

Journal Article Stenmark, Matthew; Blas, Kevin; Halverson, Schuyler; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: To analyze prognostic factors in patients with high-risk prostate cancer treated with dose-escalated external-beam radiation therapy (EBRT) and androgen deprivation (ADT). Methods and Materials: Between 1998 and 2008 at University of Michigan Medical Center, 718 men were consecutively treated with EBRT to at least 75 Gy. Seven definitions of high-risk prostate cancer, applying to 11-33% of patients, were evaluated. Biochemical failure (BF), salvage ADT use, metastatic progression, and prostate cancer-specific mortality (PCSM) were estimated by the Kaplan-Meier method and Cox proportional hazards regression. Results: Each high-risk definition was associated with increased BF (hazard ratio [HR] 2.8-3.9, p < 0.0001),more »« less
https://doi.org/10.1016/J.IJROBP.2011.04.037
Improved Biochemical Outcomes With Statin Use in Patients With High-Risk Localized Prostate Cancer Treated With Radiotherapy

Journal Article Kollmeier, Marisa; Katz, Matthew; Mak, Kimberley; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: To investigate the association between 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) and biochemical and survival outcomes after high-dose radiotherapy (RT) for prostate cancer. Methods and Materials: A total of 1711 men with clinical stage T1-T3 prostate cancer were treated with conformal RT to a median dose of 81 Gy during 1995-2007. Preradiotherapy medication data were available for 1681 patients. Three hundred eighty-two patients (23%) were taking a statin medication at diagnosis and throughout RT. Nine hundred forty-seven patients received a short-course of neoadjuvant and concurrent androgen-deprivation therapy (ADT) with RT. The median follow-up was 5.9 years. Results: The 5-more »« less
https://doi.org/10.1016/j.ijrobp.2009.12.006
Interval to Biochemical Failure Predicts Clinical Outcomes in Patients With High-Risk Prostate Cancer Treated by Combined-Modality Radiation Therapy

Journal Article Shilkrut, Mark; McLaughlin, P.; Merrick, Gregory; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: To validate the prognostic value of interval to biochemical failure (IBF) in patients with high-risk prostate cancer (HiRPCa) treated with combined-modality radiation therapy (CMRT) with or without androgen deprivation therapy (ADT). Methods and Materials: We conducted a retrospective review of HiRPCa (prostate-specific antigen >20 ng/mL, Gleason score [GS] 8-10, or clinical T stage T3-T4) treated with either dose-escalated external beam radiation therapy (EBRT) or CMRT. Interval to biochemical failure was classified as ≤18 or >18 months from the end of all therapy to the date of biochemical failure (BF). Kaplan-Meier methods and Cox proportional hazards regression were used tomore »« less
https://doi.org/10.1016/J.IJROBP.2013.03.028
Retrospective Evaluation Reveals That Long-term Androgen Deprivation Therapy Improves Cause-Specific and Overall Survival in the Setting of Dose-Escalated Radiation for High-Risk Prostate Cancer

Journal Article Blas, Kevin; Olson, Karin; Stenmark, Matthew; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: To evaluate the role of androgen deprivation therapy (ADT) and duration for high-risk prostate cancer patients treated with dose-escalated radiation therapy (RT). Methods and Materials: A retrospective analysis of high-risk prostate cancer patients treated with dose-escalated RT (minimum 75 Gy) with or without ADT was performed. The relationship between ADT use and duration with biochemical failure (BF), metastatic failure (MF), prostate cancer-specific mortality (PCSM), non-prostate cancer death (NPCD), and overall survival (OS) was assessed as a function of pretreatment characteristics, comorbid medical illness, and treatment using Fine and Gray's cumulative incidence methodology. Results: The median follow-up time was 64more »« less
https://doi.org/10.1016/J.IJROBP.2012.11.024

Similar Records